Companies Dominating the Tricuspid Insufficiency Treatment Landscape
- Abbott Laboratories
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Labcor Laboratorios Ltda.
- LivaNova, plc
- Sorin S.p.A.
- Cyberonics, Inc.
- Hologic, Inc.
- Corcym UK Limited
- Intuitive Surgical
- Sonova Holding AG
- Hill-Rom Holdings Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of tricuspid insufficiency treatment is evaluated at USD 778.33 million.
The tricuspid insufficiency treatment market size was over USD 732.86 million in 2024 and is projected to reach USD 1.83 billion by 2037, witnessing around 7.3% CAGR during the forecast period i.e., between 2025-2037. Increasing cardiovascular surgery and strong acquisition will drive the market growth.
Europe industry is expected to account for largest revenue share of 32% by 2037, impelled by rapid urbanization in the region.
The major players in the market are Labcor Laboratorios Ltda., LivaNova, plc, Sorin S.p.A., Cyberonics, Inc., Hologic, Inc., Corcym UK Limited, Intuitive Surgical, Sonova Holding AG, and others.
